Role of biomarkers in community-acquired pneumonia management

Community-acquired pneumonia (CAP) poses a significant global health threat, particularly affecting vulnerable populations. Biomarkers and scoring systems play a crucial role in diagnosing, assessing severity, and guiding treatment decisions for CAP patients. Biomarkers like C reactive protein, proc...

Full description

Saved in:
Bibliographic Details
Published in:Journal of acute disease 2024-06, Vol.13 (3), p.87-92
Main Authors: Onur, Bahaeddin, Demirbas, Hakan Barış, Gulmez, Arif
Format: Article
Language:English
Subjects:
alpha-1 antitrypsin
community-acquired pneumonia
curb-65
procalcitonin
serum amyloid a
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Community-acquired pneumonia (CAP) poses a significant global health threat, particularly affecting vulnerable populations. Biomarkers and scoring systems play a crucial role in diagnosing, assessing severity, and guiding treatment decisions for CAP patients. Biomarkers like C reactive protein, procalcitonin, and the neutrophil-to-lymphocyte ratio aid in diagnosis and severity assessment, while scoring systems such as CURB-65 and Pneumonia Severity Index classify patients into risk categories. Emerging biomarkers (uremia, elevated respiratory rate, hypotension, and age ≥ 65) like serum amyloid A and S100 proteins show promise in predicting disease severity and prognosis. However, further research is needed to determine their precise roles and clinical utility in CAP management.
ISSN:2221-6189
2221-6189
DOI:10.4103/jad.jad_65_24